Cassava sciences announces completion of an interim safety review of oral simufilam on-going phase 3 trials

Austin, texas, march 25, 2024 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a biotechnology company focused on alzheimer's disease, today announced the completion of another interim safety review of simufilam in on-going phase 3 clinical trials in patients with alzheimer's disease. a routine, scheduled meeting of a data and safety monitoring board (dsmb) recommended that both of cassava sciences' on-going phase 3 studies continue as planned, without modification.
SAVA Ratings Summary
SAVA Quant Ranking